Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Moderna's operating assets for the quarter that ended in Dec. 2023 was $9,822 Mil. Moderna's operating liabilities for the quarter that ended in Dec. 2023 was $3,329 Mil. Moderna's Total Assets for the quarter that ended in Sep. 2023 was $19,450 Mil. Therefore, Moderna's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.33.
Moderna Scaled Net Operating Assets Historical Data
The historical data trend for Moderna's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Moderna Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
|
|
|
0.10 |
-1.14 |
0.59 |
0.42 |
0.25 |
|
Moderna Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Scaled Net Operating Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.40 |
0.43 |
0.40 |
0.34 |
0.33 |
Competitive Comparison
For the Biotechnology subindustry, Moderna's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna Scaled Net Operating Assets Distribution
For the Biotechnology industry and Healthcare sector, Moderna's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Moderna's Scaled Net Operating Assets falls into.
Moderna Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Moderna's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (9822 | - | 3329) | / | 25858 |
| = | 0.25 |
where
Moderna's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Dec. 2023 ) |
| = | (Operating Assets (Q: Dec. 2023 ) | - | Operating Liabilities (Q: Dec. 2023 )) | / | Total Assets (Q: Sep. 2023 ) |
| = | (9822 | - | 3329) | / | 19450 |
| = | 0.33 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (Moderna) Business Description
Traded in Other Exchanges
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
| Stephen Hoge |
officer: President |
C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| James M Mock |
officer: Chief Financial Officer |
940 WINTER STREET, PERKINELMER, WALTHAM MA 02451 |
| Shannon Thyme Klinger |
officer: Chief Legal Officer |
200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
| Noubar Afeyan |
director, 10 percent owner |
C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
| Arpa Garay |
officer: Chief Commercial Officer |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Stephane Bancel |
director, officer: Chief Executive Officer |
320 BENT STREET, CAMBRIDGE MA 02141 |
| Juan Andres |
officer: See Remarks |
C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Paul Burton |
officer: Chief Medical Officer |
200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| David W Meline |
officer: Chief Financial Officer |
3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000 |
| Jorge M Gomez |
officer: See Remarks |
C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
| Paul Sagan |
director |
AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
| Tal Zvi Zaks |
officer: Chief Medical Officer |
C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
| Lori M. Henderson |
officer: General Counsel and Secretary |
MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778 |
| Le Goff Corinne |
officer: Chief Commercial Officer |
200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
| Elizabeth G Nabel |
director |
BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115 |
Moderna (Moderna) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRNA has been successfully added to your